HEALEY ALS Platform Trial – Regimen E SLS-005 – Trehalose

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.

For SLS-005 Trehalose clinical study queries, please contact: SLS005team@seelostx.com

For additional information, please contact:
Healey Center for ALS at Massachusetts General Hospital
Phone: 833-425-8257 (HALT ALS)
Email: healeyalsplatform@mgh.harvard.edu

ClinicalTrials.gov Identifier: NCT05136885